News >

Novel Antibody-Drug Conjugate Could Become First Targeted Therapy Approved in TNBC

Gina Columbus @ginacolumbusonc
Published: Tuesday, Nov 15, 2016

Linda T. Vahdat, MD

Linda T. Vahdat, MD

Findings from a highly anticipated, randomized, phase II trial could possibly pave the path for the FDA approval of the first targeted therapy for patients with triple-negative breast cancer (TNBC), explains Linda T. Vahdat, MD.

The METRIC study is exploring the efficacy and safety of glembatumumab vedotin (CDX-011) versus standard capecitabine in this subset of patients, particularly in those with high levels of glycoprotein NMB (gpNMB) expression (NCT01997333). The antibody-drug conjugate is a novel approach designed to target a very difficult-to-treat patient population, whose sole approved treatment option is standard chemotherapy, Vahdat stresses.

In an interview with OncLive, Vahdat, a professor of Medicine, Breast Cancer Research Program Leader at Meyer Cancer Center, at Weill Cornell Medicine and NewYork-Presbyterian, explains the goals of the METRIC trial, sheds light on how glembatumumab vedotin distinguishes itself from other agents, and how METRIC’s results, if positive, could leave a lasting impression on the treatment paradigm of TNBC.

OncLive: What is glembatumumab vedotin’s mechanism of action and how does it compare with other antibody-drug conjugates?

Vahdat: For patients with TNBC, the only really available agents right now—from a standard perspective—is chemotherapy. That is it. The only advance that has been made is administering chemotherapy to these patients. Therefore, glembatumumab works very differently. It’s an antibody-drug conjugate; the antibody part of it targets gpNMB, also known as osteoactivin. gpNMB is important for invasion and migration, so it helps the cells move around. This is linked to a chemotherapy drug known as monomethyl auristatin that is an antimicrotubule agent; it’s actually a pretty old drug.

However, the problem is they couldn’t give it in vein to people because it was too toxic. When they are able to target it just to the tumor cell, the toxicity profile is actually quite acceptable.

Anecdotally, how have you seen this drug tolerated in the patients who have enrolled thus far?

It is typically a very well-tolerated drug. The biggest side effect is that patients can get a little bit of neutropenia, which is something we deal with all the time. A small proportion of patients may get a rash, because gpNMB is sometimes expressed on the skin. Another side effect is patients do lose their hair, which is the biggest problem. As we know, the patients—very reasonably—do not want to lose their hair. Generally speaking, it’s very well tolerated.

What does the future hold for glembatumumab vedotin? Could we look at combining it with other agents?

It is hard to know what the future holds for glembatumumab vedotin. There is one thing we know if it turns out that it is more effective than standard therapy. When we see a patient’s TNBC, in addition to reconfirming the ER-, PR-, and HER2-negativity, we are going to be checking for gpNMB overexpression, so that is going to change in how we approach patients.

What are the next steps following the METRIC trial?

That is a good question. I’m not quite sure what the next steps would be. After the METRIC trial, my hope is that we have an approval of the first targeted drug for TNBC.

One of the things that are just really important when someone is diagnosed with metastatic breast cancer is that you have options. When you look at the natural history of the disease in people who do not have TNBC—say they are HER2-positive or HR-positive, called luminal breast cancers—they have lots of options. You have this big bucket that you pull of all of these options out of.

When you have patients with TNBC, you only have 1 set of options—which is chemotherapy, so they’re really very limited. Having a drug such as glembatumumab vedotin would expand the options. The expectation would be that, if you expand the options with something that is targeted, you would have better disease control and a better quality of life.

What else should the community know about the METRIC trial?

If you have TNBC and you really haven’t had too many therapies at all, it’s really good to speak to your healthcare provider to see whether or not you would be a candidate for this clinical trial. Then, contact us on We would be happy to see if you are a candidate or answer your questions, because it’s a great opportunity.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication